How can longevity biotech companies make money before drug approval?

Can longevity biotech companies make real money before a drug is approved?

Longevity biotech companies can make real revenue before drug approval, but today the most credible money comes from selling access to their science rather than from selling the eventual medicine.

That can mean licensing an experimental drug, letting a pharmaceutical company use a discovery platform, running paid R&D programs, collecting milestone payments, selling software or data tools, or commercializing another product built from the same scientific capabilities.

The amounts can already be meaningful. BioAge's collaboration with Novartis includes up to $20 million in upfront payments and research funding. UNITY Biotechnology received $5 million upfront when it licensed its α-Klotho program to Jocasta Neuroscience. Insilico Medicine, which grew out of longevity-focused AI research but now operates across drug discovery, signed a Lilly collaboration in 2026 that included a $115 million upfront payment.

Those are three very different stages of monetization. BioAge is being paid to help discover targets. UNITY monetized an existing experimental asset. Insilico had built enough technology and pipeline value to command a nine-figure upfront.

None of them had to wait for pharmacy sales.

The catch is that revenue and self-sufficiency are still very different things. A longevity biotech can bring in $10 million, $30 million or even $100 million and continue burning substantially more while running clinical trials.

That distinction runs through the whole sector.

If you want more recent data on this point, please see our latest longevity biotech market report.

Does venture capital count as revenue for a longevity biotech?

Venture capital does not count as operating revenue for a longevity biotech, even if fundraising is currently what keeps most drug developers alive.

When investors put $100 million into a biotech, the company gets cash in exchange for equity. No customer bought a product, no pharmaceutical company paid for intellectual property, and no commercial demand was proven.

An IPO works in much the same way.

That sounds obvious, but the distinction becomes important in longevity because companies can raise spectacular sums long before generating meaningful sales. A large cash balance can therefore hide a business that remains completely dependent on capital markets.

Grants sit somewhere else again. They can fund experiments without diluting shareholders and are especially useful in aging research, but they still tell us little about whether customers will eventually pay for the company's technology.

The strongest pre-approval business models create cash from outside organizations that actually want something the biotech owns: a molecule, a target, a platform, data, software or research work.

Cash source	Real commercial revenue?	Gives up equity?	Shows customer demand?
Venture capital	No	Yes	No
IPO	No	Yes	No
Debt	No	No	No
Government grant	Usually no	No	Weakly
Paid research collaboration	Yes	No	Yes
Licensing upfront	Yes	No	Yes
Development milestone	Yes	No	Yes
Software or platform sales	Yes	No	Yes
Approved drug sales	Yes	No	Yes

Can Big Pharma pay a longevity company before it even has a drug to sell?

Yes. Big Pharma is already paying longevity companies for target discovery and research years before any resulting medicine could reach patients.

BioAge gives us a clean example. The company built its platform around longitudinal human data that connects molecular changes with aging, disease and physical performance. Novartis agreed to pay up to $20 million in upfront payments and research funding to use that platform in research around aging biology and exercise.

The collaboration can eventually produce another $530 million in research, development and commercial milestones, although those later payments depend on future success.

The useful part is what has already happened.

BioAge's SEC filing for the first half of 2026 showed $5.2 million of collaboration revenue from Novartis, up from $3.9 million in the comparable period a year earlier. Of the 2026 amount, $3.8 million came from reimbursable research costs.

That is real revenue being created while the underlying therapeutic programs are still in development.

BioAge also has a separate collaboration with Lilly ExploR&D around antibodies against metabolic-aging targets.

The business logic is fairly simple. If an aging platform repeatedly identifies drug targets that pharmaceutical companies find interesting, the company does not need to commercialize every target itself. Some can become paid research projects while others stay inside its own pipeline.

For a longevity biotech with broad biology and limited capital, that can be much more practical than trying to finance ten drugs alone.

Can a longevity biotech license an experimental drug years before approval?

Yes. Licensing an experimental drug is currently one of the cleanest ways for a longevity biotech to turn scientific progress into cash before approval.

UNITY Biotechnology showed the basic mechanism with α-Klotho, an aging-related protein program originally licensed from the University of California, San Francisco.

UNITY later licensed its rights to Jocasta Neuroscience for a $5 million upfront payment. The agreement also gave UNITY potential development milestones, approval milestones and royalties on future sales.

The company therefore received money years before any commercial drug sale, while Jocasta took over much of the future development burden.

The same mechanism can operate on a much larger scale once an asset becomes more compelling.

Across biotech, pharmaceutical companies routinely pay for experimental drugs before approval. A particularly fresh example outside longevity came from Novartis, which recently agreed to pay Abogen Biosciences $575 million upfront for rights to an experimental mRNA therapy, with billions more tied to future options and milestones.

Longevity assets will not automatically command anything close to that price. The example still shows how the market works: pharmaceutical companies can place enormous value on a drug long before regulators approve it if the science, competitive position and clinical opportunity are strong enough.

For a longevity startup, reaching that point can itself become a commercialization strategy.

When a biotech deal says "$500 million," how much cash does the company actually get?

Usually far less. Headline biotech deal values can be hundreds of millions of dollars while the cash paid immediately represents only a small fraction of that number.

Goodwin reviewed life-sciences licensing and collaboration transactions completed in 2025 and found that the median potential value of early-stage deals was about $470 million.

Only 3.7% of that value came from upfront payments at the median.

Development milestones made up about 33%, while sales milestones represented roughly 64%.

That puts the economics into perspective. A theoretical $470 million deal built like the median transaction would contain only about $17 million in upfront value. The rest would depend on years of scientific, clinical and commercial success.

The structure has recently become somewhat more favorable to young biotech companies. Goodwin found that upfront payments had represented only 1.5% of median early-stage deal value one year earlier. Moving to 3.7% means more money is being pulled forward.

But the giant number in a press release still deserves skepticism.

A longevity biotech announcing a "$500 million partnership" may have secured enough immediate cash to fund a meaningful part of its next program. It probably has not received $500 million.

Typical early-stage deal component	Share of potential deal value in 2025
Upfront payment	3.7%
Development milestones	33%
Sales milestones	64%
Median total potential deal value	About $470M
Approximate upfront at the median mix	About $17M
Approximate development milestones	About $155M
Approximate sales milestones	About $301M

If you want more recent data on this point, please see our latest longevity biotech market report.

Can the drug-discovery platform itself become the product?

Yes. A strong drug-discovery platform can become a serious business before any internally developed drug is approved, and we can now see this working at meaningful scale.

Schrödinger is the clearest benchmark.

The company sells computational drug-discovery software while also developing its own medicines and participating in pharmaceutical collaborations. In the first half of 2026, Schrödinger generated $68.1 million from software products and services and another $45.9 million from drug discovery.

Its second-quarter software gross margin was 71%.

Schrödinger is therefore making money from the infrastructure used to discover drugs while its own clinical pipeline continues developing.

Insilico Medicine has built a different version of the same model around AI. In early 2026 it announced a Servier collaboration worth up to $888 million, including as much as $32 million in upfront and near-term R&D payments. A few months later, its Lilly deal brought a $115 million upfront payment and potential total value of roughly $2.75 billion. It has since added another collaboration with Takeda.

This route is especially interesting for longevity biotech because aging research can generate tools useful far beyond one medicine: biological-age models, target-discovery systems, multi-omics analysis, molecular design software and datasets.

A platform that pharmaceutical companies repeatedly pay to use changes the economics of the company. The next drug is still risky, but the underlying discovery engine already has customers.

Can longevity companies actually sell their aging data?

Yes, but aging data become far more valuable when they help discover drugs than when companies simply sell database access.

The appeal of longevity data comes from time.

Many diseases associated with aging develop over decades. A longitudinal dataset can show how biomarkers, proteins, metabolic changes and clinical outcomes evolve within the same individuals rather than comparing unrelated younger and older groups at one moment.

That kind of dataset can help identify mechanisms that ordinary cross-sectional data miss.

BioAge built much of its platform around this idea and has also worked with Age Labs on more than 17,000 samples from Norway's HUNT Biobank.

As seen above, BioAge's Novartis collaboration is already producing revenue from work tied to these human-aging datasets.

The important commercial lesson is where the customer sees the value. Pharmaceutical companies generally have little reason to pay huge amounts merely to browse another biological database. They will pay much more readily when the data generate something actionable: a drug target, a biomarker, a patient-selection method or evidence that changes a development decision.

So a longevity database on its own may become a useful data business.

A proprietary dataset that keeps producing licensable drug targets can become much more valuable.

Can longevity tests and supplements fund a biotech company?

They can generate revenue much faster than prescription drugs, but they can also pull the company into a completely different business.

Prenetics shows just how big that gap in speed can become.

Its IM8 consumer-health brand launched at the end of 2024 and generated $60.1 million of revenue during 2025. Monthly revenue went from roughly $1 million at the beginning of that year to $10 million at the end, putting the brand at a $120 million annualized run rate.

A clinical-stage longevity drug can spend the same period consuming tens of millions of dollars without producing a dollar of product sales.

Diagnostics can create similar opportunities. Companies working on biological aging already measure proteins, epigenetic changes, inflammation, metabolism and other biomarkers. Some of those capabilities can become tests or monitoring products without waiting for a novel therapeutic to complete the entire prescription-drug approval process.

The problem is that fast consumer revenue can gradually take over the company.

Supplements reward branding, subscriptions, customer acquisition and frequent product launches. Drug development rewards clinical evidence, regulatory discipline and long research cycles.

A company can do both, but success selling longevity powders, blood panels or biological-age tests tells us very little about whether its experimental medicines will work.

The model is most convincing when the commercial product feeds directly back into the science, for example through biomarkers, patient selection or longitudinal health data.

If you want more recent data on this point, please see our latest longevity biotech market report.

Can a longevity company sell an existing business to finance its drug pipeline?

Yes, and this is becoming one of the more interesting ways to fund longevity R&D without waiting for the pipeline itself to mature.

Celularity offered a recent example.

The company, which has repositioned itself around longevity and regenerative medicine, signed an agreement in 2026 covering its commercial placental-derived biomaterials portfolio. Celularity said the transaction could generate up to $35 million through upfront and milestone payments.

It also retained manufacturing rights, giving it another possible stream of biomaterials revenue.

The logic is stronger than simply raising another equity round. Celularity is monetizing an activity it had already built while moving resources toward the longevity therapeutics it wants to prioritize.

Other biotech companies can apply the same approach when they own manufacturing operations, diagnostics, research tools, legacy products or intellectual property that no longer need to stay inside the core company.

This will obviously depend on what assets already exist.

For companies that have them, selling or partnering a mature side business can buy several additional years of drug development without issuing as many new shares.

Can government funding meaningfully help a longevity biotech survive?

Yes. Government funding can cover a meaningful part of early longevity R&D, especially for small teams, and the available aging-specific programs are currently substantial.

The US National Institute on Aging says it provides more than $140 million a year through its small-business programs, including SBIR and STTR funding.

Those programs explicitly cover healthy aging, age-related disease, diagnostics, interventions and technologies for older adults.

Individual awards can also become large enough to affect a startup's financing plan. NIA currently advertises commercialization-readiness awards of up to $4.2 million, while some later-stage small-business programs can reach several million dollars.

For a company spending $3 million a year, that can transform its runway.

For one spending $100 million, it barely changes the overall funding problem.

Government money is particularly useful before an asset has enough evidence to attract a pharmaceutical partner. A grant might pay for target validation, animal studies, assay development or early manufacturing work, after which the company can approach investors or licensees with much stronger data.

We should still keep the categories clear. NIA funding gives a longevity company non-dilutive capital and scientific validation. It does not prove that a commercial customer wants the product.

Can longevity companies create separate startups around different drugs?

Yes. Splitting a broad aging platform into focused companies can make individual programs easier to finance, partner or eventually sell.

Cambrian Bio has built much of its strategy around this idea.

Rather than putting every aging program into a single conventional biotech pipeline, Cambrian works with affiliated companies focused on specific mechanisms and diseases. Its current pipeline includes programs targeting metabolic decline and other age-related biology, with assets at different stages of development.

The advantage comes from separating risks.

A drug targeting one pathway may attract a specialist investor, pharmaceutical partner or acquirer even if another program inside the broader longevity portfolio fails.

Capital can also be raised closer to the asset that needs it.

This structure becomes genuinely useful when outside investors and partners are willing to fund those companies independently. Simply creating more legal entities does nothing by itself.

For a longevity platform capable of generating far more targets than it can develop, however, spinouts create another monetization path. The parent can retain equity, licensing rights or economic interests while allowing somebody else to finance a large part of development.

That is particularly attractive in aging biology because one scientific platform can produce opportunities across metabolic disease, fibrosis, immune decline, neurodegeneration and other therapeutic areas.

Trying to develop all of them internally would be extremely expensive.

Can pre-approval revenue actually cover the cost of running a longevity biotech?

Usually no. Pre-approval revenue can reduce a longevity biotech's cash burn considerably, but currently it rarely makes a serious therapeutics company self-funding.

The numbers make that clear.

BioAge generated $5.2 million of Novartis collaboration revenue during the first half of 2026. That is useful money and, as pointed out above, it comes from a real pharmaceutical customer. Yet BioAge remains a clinical-stage company whose drug-development costs are measured in tens of millions of dollars.

Schrödinger is much further along in commercializing its technology. It generated $117.5 million of total revenue in the first half of 2026, including software, drug-discovery and contribution revenue.

Even there, operating expenses reached $74 million in the second quarter alone.

Suppose a longevity biotech spends $80 million each year and manages to generate $25 million through partnerships. The company still burns $55 million. Yet its funding problem has improved dramatically because new investors no longer have to finance every dollar of R&D.

Repeated collaboration revenue can also extend runway at precisely the time when capital markets become difficult.

So pre-approval monetization does not need to produce immediate profitability to be valuable.

If it can turn a $100 million annual financing need into $60 million, the company may survive a period that kills a competitor with no outside revenue.

Should a longevity biotech license its best drug or keep it?

Usually, a longevity biotech should license enough programs to finance the company while keeping ownership of the few assets where additional internal development could create much more value.

Licensing early gives the company cash and reduces risk, but the price is future upside.

Imagine a preclinical drug that a pharmaceutical company will license today for $15 million upfront plus milestones and royalties. If the biotech keeps funding the program and later produces compelling Phase 2 data, the same asset might command a far larger upfront payment.

Getting to that Phase 2 readout could also cost tens of millions of dollars and several years.

The company therefore has to choose where it wants to carry the risk itself.

Broad longevity platforms have an advantage here because they can generate multiple shots on goal. They might license three secondary targets, collaborate on another two and keep the most promising program inside the company.

Insilico Medicine currently shows how far this portfolio approach can go. Its public pipeline lists some programs licensed to Exelixis, Menarini and other partners, while many additional candidates remain internal or available for future licensing.

That gives the company several chances to monetize R&D without selling the entire discovery engine.

For a longevity biotech with only one drug, the decision is much harder. Licensing the lead asset can secure survival but may also leave very little proprietary value behind.

If you want more recent data on this point, please see our latest longevity biotech market report.

Which pre-approval business models work best for longevity biotech today?

Pharma collaborations, selective drug licensing and commercial discovery platforms currently look like the strongest pre-approval business models because they bring in real cash while staying connected to the therapeutics the company was built to create.

Licensing works because an experimental molecule already has value before approval.

Research collaborations work because a pharmaceutical company can pay for targets, experiments and discovery capabilities without acquiring the whole company.

Platforms become even more attractive when the same technology can serve many customers. Schrödinger's software economics show the upside: recurring commercial demand can exist independently of whether one drug succeeds.

Grants are excellent for preserving equity, although their scale is usually limited.

Consumer products can grow remarkably fast but carry a bigger strategic risk because a successful supplement brand may have little connection with the probability that a longevity drug works.

Contract research sits somewhere in between. It can bring cash in quickly, although a business based on custom scientific work generally scales less attractively than reusable software, proprietary data or drug intellectual property.

Pre-approval model	Cash can arrive early?	Potential scale	Helps validate the therapeutics business?	Main problem
Pharma discovery collaboration	Yes	High	Strongly	Partner controls part of the economics
Experimental drug licensing	Yes	Very high	Strongly	Gives away future upside
Discovery software/platform	Yes	Very high	Moderately to strongly	Hard to build a real standalone product
Data and biomarker partnerships	Yes	Medium to high	Strongly when tied to drug discovery	Raw data alone may commoditize
Diagnostics	Yes	Medium to high	Sometimes	Can become a separate business
Commercial side businesses	Yes	Medium to high	Indirectly	Only works if useful assets already exist
Government grants	Yes	Low to medium	Scientifically	Limited relative to late-stage trial costs
Research services	Yes	Medium	Somewhat	Revenue can remain labor-intensive
Supplements and consumer health	Yes	High	Weakly	Can distract from drug development

Can a longevity biotech actually become profitable before its first drug approval?

A longevity biotech can become profitable before drug approval, but today that would still be unusual unless it has built a substantial software, services, diagnostics or consumer business alongside therapeutics.

Pure drug developers have a difficult cost structure.

Researchers, clinical operations, manufacturing work, toxicology studies and trials cost money continuously. Licensing payments arrive irregularly, and milestone payments depend on events the company cannot always control.

Platform companies have a better chance because they can create repeatable revenue.

Schrödinger currently expects annual contract value from its software business to reach roughly $218 million to $228 million in 2026, while drug-discovery revenue is expected at $65 million to $75 million.

That is already a much richer commercial base than the typical clinical-stage biotech has before product approval.

Still, building a serious proprietary drug pipeline can absorb much of that cash.

We would not use profitability as the main test of whether a pre-approval business model works.

A better test is how much of the company's R&D can be paid for by customers rather than shareholders.

A company covering 30% or 40% of its annual spending through collaborations and platform revenue may remain loss-making on paper while becoming far more resilient than a competitor that funds every experiment through repeated equity rounds.

So how can longevity biotech companies make money before drug approval?

Longevity biotech companies can already make meaningful money before approval, and the best route today is to commercialize pieces of the drug-development engine while keeping enough ownership of the eventual medicines to preserve the upside.

The evidence points toward a fairly clear hierarchy.

A strong longevity company can get pharmaceutical partners to pay for access to aging biology, proprietary datasets and target discovery. Experimental drugs can then be licensed once enough evidence exists to make them valuable. Milestone payments add another layer of income as those programs move forward.

Companies with genuinely useful technology can go further by selling software or platform access. Insilico and Schrödinger show that drug-discovery infrastructure itself can become a substantial commercial product rather than remaining an internal expense.

Government grants can finance the earlier scientific work. Diagnostics, biomarker products and existing commercial assets can add more revenue where they naturally fit. Consumer health can produce much faster sales, although it carries the greatest risk of turning a biotech company into something else entirely.

The biggest mistake would be expecting one of these revenue streams to eliminate the financing problem.

Clinical drug development is simply too expensive for that in most cases.

The stronger model is a company that gradually shifts more of its costs away from shareholders. Grants finance part of the early work. Pharma partners begin paying for the platform. Selected molecules produce upfront licensing payments. Successful programs trigger milestones. A few high-conviction drugs remain inside the company long enough to preserve much larger potential upside.

That combination will not make every longevity biotech profitable before approval.

It can, however, turn a company that survives only by raising its next round into one whose science increasingly pays for the next stage of its own development.

If you want more recent data on this point, please see our latest longevity biotech market report.